Merck researchers privately sought to alter Vioxx in 2000 to reduce its cardiovascular side effects, even as the drug maker publicly downplayed a study on potential heart attack risk. That's according to a company document mistakenly given to plaintiffs lawyers for one of the many Vioxx lawsuits around the country. The document is potentially among the most damaging to emerge since drug sales were suspended because it calls into question Merck's defense that officials were convinced of Vioxx's safety.
June 23, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
This conference brings together the industry's most influential & knowledgeable real estate executives from the net lease sector.
Consulting magazine is proud to recognize this unique group of movers & shakers at our annual Rising Stars of Profession awards.
BenefitsPro Broker Expo will help attendees prepare for new issues, embrace new challenges and find new solutions.
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
Duane Morris LLP has an opening in its Houston office for a corporate associate to join its growing practice. The ideal candidate will hav...
Morrison Mahoney LLP seeks a civil litigation insurance defense attorney for its New York City office. Areas of Concentration: ...
Aaronson Rappaport Feinstein & Deutsch, LLP mourns the loss of cofounder and original Managing Partner, Mark B. Feinstein.
Lawyers of Distinction would like to announce...
Snyder Sarno D'Aniello Maceri & daCosta would like to announce that...